COMMUNIQUÉS West-GlobeNewswire

Verano Hosting Grand Opening Celebration of MÜV Bradfordville on Friday, July 17th, Elevating the Company’s Retail Footprint to 86 Florida Dispensaries and 163 Locations Nationwide
14/07/2026
MÜV Bradfordville is located in the Tallahassee area on a commercial stretch of Thomasville Road that has an average daily traffic count of 13,305 vehicles 1 MÜV Bradfordville is the Company’s second location in Leon [...]
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
14/07/2026
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term [...]
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
14/07/2026
Through a series of investments over the past year, including an additional investment made in June 2026, Weinstein has built an ownership position of more than 30% as Pluri advances its longevity and U.S. [...]
Aeroflow Sleep Donates to Beds for Kids and Project Sleep to Improve Sleep Health Equity
14/07/2026
Both donations reinforce Aeroflow Sleep’s commitment to closing gaps in healthcare access and promoting healthy sleep for all ASHEVILLE, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Aeroflow Sleep , a nationwide provider of [...]
FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer
14/07/2026
Phase 1/2 trial of SOT109 in patients with advanced unresectable or metastatic colorectal cancer expected to commence in Q3 2026 PRAGUE and BASEL, Switzerland and BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- SOTIO Biotech [...]
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia
14/07/2026
Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo. The LiBBY study [...]
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
14/07/2026
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) New analyses of Phase 2b [...]
SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026
14/07/2026
EMJX Shifted from “Stress” to “Mixed” for Bitcoin Company Files Updated Investor Presentation Outlining Performance and Strategy Management to Host Fireside Chat Today at 10:30am ET NORTH PALM BEACH, Fla., July 14, 2026 [...]
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
14/07/2026
Sutacimig Phase 2 long-term extension (LTE) data show sustained bleed reduction and manageable safety and tolerability; Phase 3 initiation planned 2H 2026 Preclinical data for sutacimig in Factor VII deficiency (FVIID) [...]
Adneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance Cebranopadol in Greater China
14/07/2026
Agreement Grants Conba Rights for the Development and Commercialization of Cebranopadol for Pain Across Mainland China, Hong Kong, Macao and Taiwan, representing an important step in expanding the global potential of [...]
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
14/07/2026
SYDNEY, AUSTRALIA, July 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new [...]
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
14/07/2026
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated off-the-shelf iMSC platform [...]
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
14/07/2026
Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote SOLANA BEACH, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, [...]
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
14/07/2026
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is [...]
Transactions in connection with share buy-back program
14/07/2026
Company announcement no. 25 - 26 14 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
14/07/2026
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and [...]
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
14/07/2026
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion [...]
Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology
14/07/2026
Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of disease from human genetics OXFORD, United Kingdom, July 14, 2026 (GLOBE NEWSWIRE) -- [...]
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
14/07/2026
Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once [...]

Pages